Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

CMMB Chemomab Therapeutics Ltd

0,8898

0,0298 (3,47%)

Vor Marktöffnung

Zuletzt aktualisiert: 14:23:02

Verzögert um 15 Minuten

Biotech Shares Massively Bid Up Before Opening Bell

A Biotech stock based out of Tel Aviv has found tremendous success so far during Tuesday’s session after it was announced that the Patent Offices in Brazil and Israel have...

To read the full story on AllPennyStocks.com, click here.

Chemomab Therapeutics (NASDAQ:CMMB)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Chemomab Therapeutics Charts.

Chemomab Therapeutics (NASDAQ:CMMB)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Chemomab Therapeutics Charts.

News Chemomab Therapeutics Ltd

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
Freitag 17 Mai 2024 (4 Tage vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 9 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Donnerstag 9 Mai 2024 (2 Wochen vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 8 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Mittwoch 8 Mai 2024 (2 Wochen vor) • GlobeNewswire Inc.

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
Donnerstag 2 Mai 2024 (3 Wochen vor) • GlobeNewswire Inc.

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
Mittwoch 24 April 2024 (4 Wochen vor) • GlobeNewswire Inc.

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
Donnerstag 18 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
Dienstag 2 April 2024 (2 Monate vor) • GlobeNewswire Inc.

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
Montag 25 März 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 7 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
Donnerstag 7 März 2024 (2 Monate vor) • PR Newswire (US)

Weitere Chemomab Therapeutics Ltd News-Artikel

First Tidal Acquisition

Helgeland Sparebank

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen